The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine

Lung cancer is the leading cause of cancer related mortality in Canada and USA. Majority of the patients present in advanced stage of the disease and of these only about 2% will be alive at 5 years. NSCLC is the most common form of lung cancer, accounting for approximately 87% of cases. Systemic che...

Full description

Bibliographic Details
Main Author: Barbara Melosky
Other Authors: Vera Hirsh
Format: eBook
Language:English
Published: Frontiers Media SA 2015
Series:Frontiers Research Topics
Subjects:
Online Access:
Collection: Directory of Open Access Books - Collection details see MPG.ReNa
LEADER 02988nma a2200373 u 4500
001 EB001967428
003 EBX01000000000000001130330
005 00000000000000.0
007 cr|||||||||||||||||||||
008 210512 ||| eng
020 |a 9782889195435 
020 |a 978-2-88919-543-5 
100 1 |a Barbara Melosky 
245 0 0 |a The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine  |h Elektronische Ressource 
260 |b Frontiers Media SA  |c 2015 
300 |a 1 electronic resource (140 p.) 
653 |a Anaplastic lymphoma kinase 
653 |a personalized medicine 
653 |a Epidermal growth factor receptors 
653 |a Medicine / bicssc 
653 |a Non small cell lung cancer 
653 |a Quality of Life 
653 |a Echinoderm microtubule associated protein like 4 
653 |a KRAS 
700 1 |a Vera Hirsh 
041 0 7 |a eng  |2 ISO 639-2 
989 |b DOAB  |a Directory of Open Access Books 
490 0 |a Frontiers Research Topics 
500 |a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/ 
024 8 |a 10.3389/978-2-88919-543-5 
856 4 2 |u https://directory.doabooks.org/handle/20.500.12854/61307  |z DOAB: description of the publication 
856 4 0 |u http://journal.frontiersin.org/researchtopic/2504/the-treatment-of-metastatic-non-small-cell-lung-cancer-nsclc-in-new-era-of-personalised-medicine  |7 0  |x Verlag  |3 Volltext 
082 0 |a 610 
520 |a Lung cancer is the leading cause of cancer related mortality in Canada and USA. Majority of the patients present in advanced stage of the disease and of these only about 2% will be alive at 5 years. NSCLC is the most common form of lung cancer, accounting for approximately 87% of cases. Systemic chemotherapies have been used to treat metastatic NSCLC for decades, but the improvements of outcomes have reached a plateau. Recent advances in understanding signalling pathways for malignant cells, their interconections,the importance of various receptors and biomarkers and the interplay between various oncogenes have led to the development of targeted treatments that are improving both efficacy and safety of the treatments. Knowledge about the advantages of treatments with the targeted agents in metastatic NSCLC is growing rapidly. Combining various targeted agents or sequencing them properly will be important in the era of personalised medicine and overcoming development of the resistence to various targeted agents will be challenging. The importance of a team work,from the diagnosis through various treatments, to supportive care, from the interventional radiologists, pneumologists or surgeons, who have to obtain a satisfactory tumor tissue specimen, to pathologists, radiation and medical oncologists, to supportive care specialists, will be described in our publications. We will cover completely present and future approaches to personalised medicine in this rapidly evolving field of metastatic NSCLC.